Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Rhomboid Proteases in Plasmodium spp. : Biology, Functional Roles, and Therapeutic Potential.Acta parasitologica · 2026
   Review
2. Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatment.Malaria journal · 2025
   Article
3. T-follicular helper cell profiles differ by malaria antigen and for children compared to adults.eLife · 2025
   Article
4. Properties of Plasmodium falciparum with a Deleted Apicoplast DNA Gyrase.Antimicrobial agents and chemotherapy · 2021
   Article
5. Toward New Transmission-Blocking Combination Therapies: Pharmacokinetics of 10-Amino-Artemisinins and 11-Aza-Artemisinin and Comparison with Dihydroartemisinin and Artemether.Antimicrobial agents and chemotherapy · 2021
   Article
6. Antimalarial drug resistance in the Central and Adamawa regions of Cameroon: Prevalence of mutations in P. falciparum crt, Pfmdr1, Pfdhfr and Pfdhps genes.PloS one · 2021
   Article
7. Efflux pumps and antimicrobial resistance: Paradoxical components in systems genomics.Progress in biophysics and molecular biology · 2019
   Review
8. Partner-Drug Resistance and Population Substructuring of Artemisinin-Resistant Plasmodium falciparum in Cambodia.Genome biology and evolution · 2017
   Article
9. Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?Infectious diseases of poverty · 2017
   Review
10. Modeling Key Malaria Drugs' Impact on Global Health: A Reason to Invest in the Global Health Impact Index.The American journal of tropical medicine and hygiene · 2016
    Article
11. Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99-411, with long acting prescription antimalarials, lumefantrine and piperaquine.Scientific reports · 2015
    Article
12. Antimalarial activity of kinase inhibitor, nilotinib, in vitro and in vivo.The Journal of antibiotics · 2015
    Article
13. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.The American journal of tropical medicine and hygiene · 2014
    Article

Corrections and comments

• Comment on
  Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children.2014

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as